All In Biotech

NDA 022063 · Takeda Pharms USA

Mydayis

Amphetamine Aspartate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate · Oral

Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Jun 20, 2017

Approved uses

2

Original approval plus efficacy supplements

Registered trials

5

3 Phase 3, 0 recruiting

FAERS reports

879

184 serious, 5 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ABUSE, MISUSE, AND ADDICTION MYDAYIS ® has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including MYDAYIS, can result in overdose and death [see Overdosage (10) ] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing MYDAYIS, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout MYDAYIS treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions (5.1) , Drug Abuse and Dependence (9.2) ]. WARNING: ABUSE, MISUSE, AND ADDICTION...

What it is approved for

From the label in effect Apr 30, 2026.

MYDAYIS is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older [see Clinical Studies (14) ] . MYDAYIS is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older. ( 1 ) Limitations of Use : Pediatric patients 12 years and younger experienced higher plasma exposure than patients 13 years and older at the same dose and experienced higher rates of adverse reactions, mainly insomnia and decreased appetite. ( 8.4 ) Limitations of Use : Pediatric patients 12 years and younger experienced higher plasma exposure than patients 13 years and older at the same dose, and experienced higher rates of adverse reactions, mainly insomnia and decreased appetite [see Use in Specific Populations (8.4) ] .

Mechanism: Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD is not known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • MYDAYIS · AMPHETAMINE ASPARTATE 9.375MG; AMPHETAMINE SULFATE 9.375MG; DEXTROAMPHETAMINE SACCHARATE 9.375MG; DEXTROAMPHETAMINE SULFATE 9.375MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB2
  • MYDAYIS · AMPHETAMINE ASPARTATE 3.125MG; AMPHETAMINE SULFATE 3.125MG; DEXTROAMPHETAMINE SACCHARATE 3.125MG; DEXTROAMPHETAMINE SULFATE 3.125MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB2
  • MYDAYIS · AMPHETAMINE ASPARTATE 12.5MG; AMPHETAMINE SULFATE 12.5MG; DEXTROAMPHETAMINE SACCHARATE 12.5MG; DEXTROAMPHETAMINE SULFATE 12.5MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB2
  • MYDAYIS · AMPHETAMINE ASPARTATE 6.25MG; AMPHETAMINE SULFATE 6.25MG; DEXTROAMPHETAMINE SACCHARATE 6.25MG; DEXTROAMPHETAMINE SULFATE 6.25MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB2

Clinical trials

Interventional ClinicalTrials.gov studies with "Amphetamine Aspartate" as an intervention, any sponsor and status, largest first.

All 5 trials
  • ShireTakeda (TAK)

    NCT00152035 · 505 participants · Start Mar 10, 2005 · Primary completion Nov 7, 2006

    Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate. · For: Attention Deficit Disorder With Hyperactivity

  • ShireTakeda (TAK)

    NCT00152022 · 412 participants · Start Apr 25, 2005 · Primary completion Nov 4, 2005

    Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate. · For: Attention Deficit Disorder With Hyperactivity

  • ShireTakeda (TAK)

    NCT00150579 · 240 participants · Start Jan 27, 2005 · Primary completion Jun 14, 2005

    Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate · For: Attention Deficit Disorder With Hyperactivity

  • ShireTakeda (TAK)

    NCT00202605 · 72 participants · Start Sep 29, 2005 · Primary completion Jan 6, 2006

    Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate · For: Attention Deficit Disorder With Hyperactivity

    Sites: Little Rock, Arkansas; Irvine, California; Las Vegas, Nevada · 4 sites in all

  • ShireTakeda (TAK)

    NCT03327402 · 24 participants · Start Mar 13, 2018 · Primary completion Oct 5, 2018

    Drug: SHP465 · For: Attention Deficit Hyperactivity Disorder (ADHD)

    Sites: Little Rock, Arkansas; Orlando, Florida; Evansville, Indiana · 8 sites in all

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective219
  • fatigue61
  • insomnia57
  • headache53
  • anxiety49
  • off label use49
  • feeling abnormal47
  • product availability issue47
  • no adverse event46
  • inability to afford medication43
  • somnolence41
  • insurance issue39

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201783
2018239
201997
202079
202195
202262
202381
202472
202540
202631

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Mydayis (Dextroamphetamine/Amphetamine)

2024 spending

$1.3M

Beneficiaries

737

3,902 claims

Per beneficiary

$1,797

$11.00 per unit

View as table
YearSpending
2020$1,529,481
2021$1,649,959
2022$1,826,993
2023$2,533,863
2024$1,324,735

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.